Russia: New crown vaccine developed for nasal drips

Marksutov said the center had selected the three most promising of the six vaccines it had developed for clinical trials by the end of JuneOne of the vaccines, based on peptide antigens, is not only different in functional origin, but also different immune methods and programs, it is not the usual intramuscular injection of medicine, but the nasal drip-type administrationThe technical route of the vaccine was well validated when the Ebola virus vaccine was developed in 2018Animal testresultsthe three vaccines showed that after the vaccination, the animals did not experience elevated body temperature and no adverse reactions were observedThis suggests that animals show good tolerance to vaccinationTo monitor possible changes in the animal's lungs, the researchers also used AnX-ray machinetor to confirm it, Maksutov saidthe Russian National Science Center for Virology and Biotechnology, located in Siberia, is a leader in the development of a new coronavirus vaccineUsing methods such as recombinant protein vaccines and synthetic vaccines, the Centre has worked vaccine development on six technical routes, including influenza, measles and hydrohersis viruses in the recombinant protein vaccine and synthetic vaccine technical routes, and six vaccines were tested in animals on 13 April, the Russian Ministry of Health' National Research Center for Epidemiology and Microbiology in Gamarea, in cooperation with the Russian Ministry of Defense, developed a adenovirus vector vaccine, and all the center's research and development of new coronavirus vaccine staff have been testedThe center's director, Kinzburg, said tests showed the vaccine performed well and had produced protective antibodiesBut he noted that the move should not be seen as a vaccine trial, a self-preservation effort to keep working onWHO has included the results of nine new coronavirus vaccines developed in Russia on the shortlist, six of which were developed by the National Scientific Centre for Vector Virology and Biotechnology, two from Biocad, a Russian biopharmaceutical company, and one from the StPetersburg Institute of Vaccines and Serums.